Calistoga Pharmaceuticals, the Seattle-based developer of drugs for cancer and inflammatory diseases, said today its lead candidate for blood cancers appears to be working against tumors by disrupting chemokine signals and the tumor microenvironment. The findings were presented today at the European Hematology Association meeting in Barcelona. We reported last week on how the Calistoga drug, CAL-101, appears to be shrinking tumors in patients with chronic lymphocytic leukemia, slow-growing forms of non-Hodgkin’s lymphoma, and mantle cell lymphoma.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
